CanBas Co

CanBas Co Long-Term Investments

The Long-Term Investments of CanBas Co (4575.T) as of Nov 4, 2026 is 31.00 M JPY. In the previous year, Long-Term Investments was 31.00 M JPY — a change of 0.00% (lower).

Long-Term Investments

31.00 MJPY

YoY

0.00%

Last updated:

Long-Term Investments of CanBas Co is 2019 31.00 M JPY. Long-Term Investments of CanBas Co was 2018 31.00 M JPY. It decreases by 0.00% lower compared to the previous year.

The CanBas Co Long-Term Investments history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Long-Term Investments
Date
Long-Term Investments
Jan 1, 2014
21.00 M JPY
Jan 1, 2015
20.00 M JPY
Jan 1, 2016
20.00 M JPY
Jan 1, 2017
19.00 M JPY
Jan 1, 2018
31.00 M JPY
Jan 1, 2019
31.00 M JPY
The CanBas Co Long-Term Investments history
YEARLong-Term InvestmentsYoY
31.00 MJPY0.00%
31.00 MJPY+63.16%
19.00 MJPY-5.00%
20.00 MJPY0.00%
20.00 MJPY-4.76%
21.00 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CanBas Co Stock analysis

What does CanBas Co do? CanBas Co., Ltd. generates revenue through pharmaceutical research and development, focusing on basic anticancer drug discovery and early clinical development. The company develops drug discovery concepts, selects candidate compounds, conducts simple animal studies, and analyzes basic data on anticancer drug candidates entering development. It also performs preclinical studies for clinical trial applications and manages the initial phase of clinical trials. The primary buyers of these services are pharmaceutical companies seeking to advance their anticancer drug pipelines through early-stage research and development. CanBas Co., Ltd. operates with a team of 12 full-time employees, specializing in anticancer drug research. The company's services are tailored for pharmaceutical firms requiring expertise in early-stage drug development, particularly in the discovery and preclinical phases. Its focus on basic anticancer drug research and early clinical development positions it as a specialized provider in the pharmaceutical R&D sector. The firm's business model relies on providing comprehensive research services to pharmaceutical companies, including concept development, compound selection, animal studies, and data analysis. These services are critical for pharmaceutical firms to progress anticancer drug candidates from discovery to early clinical stages, ensuring efficient and effective development pathways for new treatments. CanBas Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CanBas Co stock

Long-Term Investments of CanBas Co is 31.00 M JPY in 2019.

Long-Term Investments of CanBas Co changed from 31.00 M JPY to 31.00 M JPY, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Investments CanBas Co since 2006 – with annual values, charts, and detailed analysis.

Long-term investments include equity stakes, bonds, and other securities held for more than one year. They represent strategic or financial investments for future returns.

Long-Term Investments's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Long-Term Investments's CanBas Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — CanBas Co

All Key Metrics — CanBas Co